Liquid Biopsy cfDNA, EGFR
Liquid Biopsy
| Test Name | LIQUID BIOPSY, cfDNA, EGFR |
| Clinical Utility | • Simple non-invasive blood draw. • Not dependent on availability of tissue sample. • Utilizes circulating cell-free DNA (cfDNA) to provide comprehensive tumor mutational. profle. • This is an in-house developed test useful. for the detection of exon 19 deletion (p.E746_A750deletion), Exon 20 point mutation (T790M) and Exon 21 point mutation (L858R). |
| Patient Selection | Patients with limited traditional. cancer therapy options: • Metastatic Cancer • Refractory or resistant cancer |
| Technology | Digital. Droplet PCR |
| TAT | Mon / Thu 9 am; Report Fri / Tue |
| Specimen | 10 mL Whole blood in 1 Streck tube. |
Comparison between tissue biopsy & liquid biopsy
| Tissue Biopsy | Liquid Biopsy |
| Lack of tumor heterogeneity | Representation of intra-tumoral complexity |
| Not an option in severely ill patients | Can be a substitute for primary biopsy in severely ill patients |
| No periodic monitoring for progression/ recurrence | Dynamic monitoring of molecular changes for progression/recurrence |
| Obtained by surgery, an expensive procedure. Not easily obtained | Body fluid/blood is collected by a simple inexpensive procedure. Easily obtained |
| Some pain and risk involved | Minimal pain and risk involved |
| Invasive and uncomfortable (possibility of clinical complications) | Minimally invasive |
When to use Liquid Biopsy?
• Patients under treatment to monitor therapy response and drug resistance
• Patients whose tumor is inaccessible
• Patients in remission for monitoring cancer recurrence
• Patients diagnosed with cancer for molecular profiling and therapy match
• Patients who have failed other treatments
• Patients with metastatic cancer
Post a Comment
